Thomas S.
Uldrick, Jr.
M.D.
M.S.
Photo: Fred Hutch
Education, Training, Board Certifications
- M.D., State University of New York Downstate Medical Center
- M.S., Columbia University
- Residency, New York Presbyterian Hospital
- Fellowship, New York Presbyterian Hospital
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Clinical Expertise
- HIV-related cancers
- Immunotherapy
- Lymphoma
- Kaposi sarcoma
- Global health
Affiliations
Publications
Research and/or clinical interests
Dr. Thomas Uldrick is an international expert on HIV-related cancers, especially lymphoma, Kaposi sarcoma and other diseases caused by Kaposi sarcoma herpesvirus (KSHV). KS remains one of the most common cancers in HIV-infected people worldwide, with a major disease burden in East Africa. One of his key research interests is designing clinical trials, including immunotherapy studies, that accelerate the delivery of the most promising scalable curative cancer therapies to low-income settings. He explores whether a type of immunotherapy known as a checkpoint inhibitor may improve outcomes in patients with both advanced cancers and HIV. By showing that this class of drug is safe in certain cancer patients with HIV, he is helping break down unnecessary barriers to including them in clinical trials.
Current projects include:
- Evaluating the safety and efficacy of anti-PD-1 therapy in patients with HIV-associated Kaposi sarcoma
- Evaluation of rituximab hyaluronidase combined with standard chemotherapy for Burkitt lymphoma, diffuse large B-cell lymphoma and KSHV-associated multicentric Castleman disease in East Africa
- Evaluation of the immune effects of HIV that increase risk of human papilloma virus-associated cancers